TABLE 4

Effect on islet survival of thymectomy before intravenous administration of in vivo allopeptide-primed syngeneic T-cells

GroupImmunosuppression (intraperitoneal ALS on day −7)Intravenous injection of P5-primed T-cellsIslet donorGraft survival (days)MST ± SD (days)
IWF8, 8, 8, 88.0 ± 0.0
IIBN6, 8, 9, 98.0 ± 1.4
III0.5 mlWF11, 11, 12, 1311.8 ± 1.0
IV0.5 ml2 × 107 T-cellsWF12, 14, 14, 1614.0 ± 1.6
V0.5 ml2 × 107 T-cellsBN6, 7, 107.7 ± 2.1
  • ACI recipients were thymectomized 10 days before intravenous injection of 2 × 107 alloMHC peptide (P5)-primed T-cells obtained at 7 days from syngeneic rats inoculated intravenously with 2 × 106 P5-pulsed myeloid self-DC. The animals were transplanted with WF or BN islets 7 days after intravenous injection of P5-primed syngeneic T-cells combined with or without 0.5 ml ALS intraperitoneal immunosuppression.